Innovative technology based on phages and data, developed to eliminate specific bacteria.

Our production process is carried out according to pharmaceutical quality standards with exceptional yields.

Lab

Our HQ in Santiago, Chile, occupies four floors in the UC Anacleto Angelini Innovation Center. It’s a dynamic and collaborative space with infrastructure meeting international standards.

Equipped with cutting-edge technology, our state-of-the-art laboratories seamlessly advance from diagnosis to producing powerful bacteriophage solutions. These high-tech facilities and equipment allow precise and effective operation across all our processes.

Our multidisciplinary teams utilize these resources to innovate, ensuring seamless integration of science and technology within our advanced infrastructure.

Our scientific process made simple

Design
2.
Discovery
1.
Diagnosis
3.
Development
4.
Formulation
Production
7.
Production
8.
Regulatory
6.
Trial
5.
Scaling
Esto es otra pagina
Go Back
Molecular Diagnosis
Bioinformatics
Go Back
Research Project & Phages Lab
Go Back
Artificial Intelligence
Research Projects & Phages Lab
Go Back
Research Projects & Phages Lab
Go Back
MSAT
Go Back
Veterinary
Go Back
Manufacturing
Operations
Go Back
Global Regulatory Affairs

Molecular Diagnosis:
RAPID BACTERIAL IDENTIFICATION WITH CUTTING-EDGE TECHNOLOGIES

Our team of real-time PCR and WGS specialists can process our clients’ samples, sequence DNA libraries, and identify the problematic bacteria in 25 days. We implement new technologies, processes, and top-level team players to generate comprehensive profiles of target bacteria.

Bioinformatics:
REVOLUTIONIZING ANALYSIS THROUGH INNOVATION AND AUTOMATION

Our team of bioinformaticians with extensive computational biology, genomics, and data science experience reduced the time of analysis from 12 months to 10 hours through new scripts, parallelization, and automation.

Research Projects & Phages Lab (DISCOVERY):
PRECISION PHAGE ANALYSIS FOR TARGETED BACTERIAL SOLUTIONS

In this step, the team isolates and characterizes the genomics, kinetic parameters, and physicochemical properties of new phages. Using the double-layer agar technique they test the phages with the potential to interact with the problem bacteria from a client. We have a huge library of characterized bacteriophages.

ARTIFICIAL INTELLIGENCE:
PIONEERING PREDICTIONS FOR PHAGE-BACTERIA INTERACTIONS

Our AI team developed proprietary pipelines that accurately predict the target bacteria’s lytic susceptibility against a phage. These workflows help us select the best candidates for a phage cocktail. To that end, our team characterizes the bacteria’s genome, the phage’s genome, and historical data detailing interactions between phages and bacteria.

Research Projects & Phages (DEVELOPMENT):
BEST PERFORMING PHAGE TESTING

The best-performing phages are next tested through quantitative assays against the client’s bacterial collection. The designed cocktails are evaluated quantitatively in vitro, and the most effective phages in terms of lytic activity will compose the phage cocktail.

Research Projects & Phages Lab(formulation)
CRAFTING CLIENT-CENTRIC COCKTAIL PROTOTYPES

Our new cocktail prototypes are formulated to minimize modifications to our clients’ SOPs. The formulations consist of excipients that must meet the following criteria:

  • Preserve the integrity of bacteriophages for long periods of time.
  • Regulatory approval for use in animals.

MSAT:
CRAFTING PERFECT PHAGE SCALING CONDITIONS

Our Manufacturing, Science & Technology team (MSAT) serves as the bridge between Development and Production. They are in charge of standardizing the optimal conditions to scale up the phages comprising a product.

Veterinary
ON-SITE PRODUCT IMPLEMENTATION EXPERTISE

This international team evaluates the efficacy of our products under real conditions as well as the productive parameters. They go wherever our clients are and assist in setting up the product implementation.

MANUFACTURING:
COST-EFFICIENT SOLUTIONS FOR INDUSTRIAL LEVELS

We house the first cost-efficient phage manufacturing facility in the world. Through our manufacturing team, we produce bacteriophage cocktails with immense scalability. Additionally, the yields we obtain with our liquid zootechnical additives allow us to administer them to millions of animals each year.

OPERATIONS:
THE BEST SUPPORT TO ENHANCE OUR FINAL PROCESS

Our operations team ensures adherence to good manufacturing practices and other relevant standards by implementing and maintaining quality assurance systems at each development and production stage. Additionally, the team manages the logistics of transporting and distributing biotechnological products, ensuring timely delivery in compliance with transportation regulations.

GLOBAL REGULATORY AFFAIRS:

NAVIGATING DIVERSE MARKETS WITH A DEDICATED TEAM OF SPECIALISTS

Our global regulatory affairs team makes sure that our products are approved by the regulatory authorities of each target market.

Natural defenders on the front line

Bacteriophages are viruses with the ability to infect and destroy specific bacteria. They are abundantly and diversely present in the environment and inhabit the gastrointestinal tract of humans and animals, where they play an important role in regulating the diversity and population of different bacteria.

Bacteriophages: safe, effective, and specific.

Bacteriophages do not contain toxic or harmful elements for health, development, or reproduction. During product development, we select bacteriophages free of antibiotic-resistant genes.

Performance platform with data intelligence.

Our platform allows for historical and real-time tracking of critical metrics and key data for each project based on its performance.

Metrics

More than 15,000 sq ft of infrastructure

The central hub facility in Chile is composed of laboratories and offices strategically positioned across four separate floors, embodying our dedication to cutting-edge practices and seamless functionality. Expanding our reach, we are actively engaged in operations spanning Chile and Brazil.

Only 25 days to process and sequence samples

Our Molecular Diagnostics team is equipped with top-notch technology to have swift results and has been able to reduce the diagnosis time of pathogenic bacteria from 6 months to only 25 days.

Full bioinformatics analysis in 10 hours

This rapid turnaround enables swift interpretation of large datasets, providing insights into genetic information and functional annotations. It’s particularly crucial for dynamic research environments, allowing for timely decision-making and accelerating the pace of our diagnosis.

2,990 fully characterized pathogenic bacteria

Our extensive bacteria repository not only accelerates the identification of target bacteria but also positions us at the forefront of pioneering research. This invaluable resource empowers us to continuously expand our understanding, of infectious disease, enabling the development of highly targeted and effective phage therapies to combat pathogenic bacteria.

A library of 800 different phages

This rich collection allows us to swiftly pinpoint suitable phages for combating specific pathogenic bacteria. Our extensive phage library catalyzes innovation, offering a dynamic toolkit to tailor precise interventions and advance the development of cutting-edge phage solutions, marking us as leaders in the fight against harmful pathogens.

We’ve developed a cocktail with 93% in vitro efficacy

This proves the significant advantages of phages as a powerful possibility to combat bacterial infections. The precision enhances the potential for successful outcomes and reinforces the ability to specifically target and neutralize pathogenic bacteria, offering a strong shield against potential infections.

Latest Updates

Interested in becoming a PHAGELAB® partner?